»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ 3?}W0dZ$d
*=6,}rX"I
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 /c`s$h4-
CL~21aslI
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© ndsu}:my
1.Antigen presenting cell£¨APC£© uSAb
2.Activation induced cell death£¨AICD£© uV\ _j3,2
3.Chemokine K*ZH<@o4
4.Major histocompatibility complex£¨MHC£© _
l i\b-
5.immunotolerance EmaVd+Sw
:sMc}k?9S
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© Esc*+}ck
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ A?
=(q
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷Óà 33R_JM{
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ L4)@lmd3
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿ UF
g N@
5.±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã
5y}kI
*@M7J
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© K?y!zy
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ .] S{T
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ D]I]I!2c
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ ]Z@+
|&@L
.kBZ(`K
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ }ph;~og}y
;'o:1{Y
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 (Ea)`'/
;K'1dsA
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩ #>SvYP
1.Antigenic determinant
)xJo/{?
2.IgSF )8H5ovj.
3.MBL;¾¶ }tH$/-qnJE
4.chemokine 0A~zuK
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ </K"\EU
6.TCR-CD3¸´ºÏÎï [*-DtbE
k
7.FADD£¨Fas-associated protein with death domain£© mSWh'1]b.~
8.AIDS /<(d.6T[}:
9.Tumor rejection antigen EM_`` 0^
10.AICD D4:c)}
))M; .b.D
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ _084GK9{W
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£© 3^>D |
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ T)IH4UO
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ k1A64?p
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì S`LS/)
w[>/(R7im
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ *
/S=9n0
)~q@2^
>?b9Xh
רҵ¿Î ÃâÒßѧ *"N756Cj
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê JrF\7*rh9
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell #ii,GN~N
5. Fc¦Å receptor 6. Cytokine t]Ey~-Rx
¶þ¡¢ ÎÊ´ðÌâ VP4W~;UV|\
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØÉ±É˰Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 `(|jm$Q
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ Lb
GyD;#_
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁܰÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ `TBI{q[y
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâÐ©ÌØµãµÄÉúÎïѧÒâÒ壿 qMAH~P0u
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦Óᣠ"{0
o"k
:tu_@3bg-
,|4%YaN.3
kc d~`+C
|V2+4b,
g;U f?
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ z.f~wAT@<
q9j9"M'
2M>Y3Q2Yv
רҵ¿Î ÃâÒßѧ sF?N vp
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê W{\){fr6O
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen
j|f$:
j
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin O>^0}
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test 9,|&+G$
9. Hybridoma technic 10.Mitogen #NM.g
11.Dentritic cell 12.Immunoproliferation bdiyS.a-
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ `jR;Rcz
C
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨ÄöÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ 6g@@V=mf
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦Óᣠs1XW}Dw
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£ Z7&Bn